Calcium sensitizer agents: A new class of inotropic agents in the treatment of decompensated heart failure

International Journal of Cardiology

Volumn 103, Issue 3, 2005, Pages 248-255

  Perrone, Sergio V ^a   Kaplinsky, Edgardo J ^b  

^a Instituto de Investigaciones Neurologicas Raul Carrera   (Argentina)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Calcium sensitizer agents; Heart failure; Inotropic agents; Levosimendan

Indexed keywords

4,5 DIHYDRO 6 [4 (4 PYRIDYLAMINO)PHENYL] 3(2H) PYRIDAZINONE; 5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; ADRENALIN; AMIODARONE; AMRINONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM SENSITIZER; CYCLIC AMP; DOBUTAMINE; DOPAMINE; ENOXIMONE; INOTROPIC AGENT; ISOPRENALINE; LEVOSIMENDAN; MILRINONE; NORADRENALIN; PHOSPHODIESTERASE III INHIBITOR; PIMOBENDAN; PIPERANOMETOZINE; POTASSIUM CHANNEL; XAMOTEROL;

CALCIUM CELL LEVEL; CARDIOGENIC SHOCK; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; EXERCISE; HEART ARRHYTHMIA; HEART FAILURE; HEART INDEX; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEMODYNAMIC MONITORING; HUMAN; HYPOTENSION; LOW DRUG DOSE; LUNG CAPILLARY PRESSURE; MORTALITY; OXYGEN CONSUMPTION; PRIORITY JOURNAL; REVIEW; VASODILATATION;

ARRHYTHMIA; CARDIOTONIC AGENTS; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; PYRIDAZINES;

EID: 23644460318     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2004.12.012     Document Type: Review

References (76)

1. J.G.F. Cleland, A. Khand, and A. Clark The heart failure epidemic: exactly how big is it? Eur Heart J 22 2001 623 626
2. J.J. McMurray, and S. Stewart Epidemiology, aetiology, and prognosis of heart failure Heart 83 2000 596 602
3. American Heart Association: 1999 Heart and Stroke Statistical Update. Dallas, Texas: American Heart Association: 1998.
4. P. Jain, B.M. Massie, W.A. Gattis, L. Klein, and M. Gheorghiade Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization Am Heart J 145 2003 S3 S17
5. S. Thackray, J. Easthaugh, N. Freemantle, and J.G.F. Cleland The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis Eur J Heart Fail 4 2002 515 529
6. J.J. McMurray, and S. Stewart Epidemiology, aetiology, and prognosis of heart failure Heart 83 2000 596 602
7. S. Stewart (University of Australia) Prognosis of patients with heart failure compared with common types of cancer Heart Fail Monit 3 2003 87 94
8. A. Mosterd, and A.W. Hoes Reducing hospitalizations for heart failure Eur Heart J 23 2002 842 845
9. M.T. Olivari Behavioral and environmental factors contributing to the development and progression of congestive heart failure J Heart Lung Transplant 19 8 Suppl. 2000 S12 S20
10. A. Mosterd, and A.W. Hoes Reducing hospitalizations for heart failure Eur Heart J 23 2002 842 845
11. L.W. Stevenson Tailored therapy to hemodynamic goals for advanced heart failure Eur J Heart Fail 1 1999 251 257
12. M.C. Deng, M. Weyand, and D. Hammel Selection and management of ventricular assist device patients: the Muenster experience J Heart Lung Transplant 19 8 Suppl 2000 S77 S82
13. D.O. Taylor, L.B. Edwards, and P.J. Mohacsi The registry of the international society for heart and lung transplantation: twentieth official adult heart transplant report-2003 J Heart Lung Transplant 22 2003 616 624
14. M. Packer, and C.V. Leier Survival in congestive heart failure during treatment with drugs with positive inotropic actions Circulation 75 5 Pt. 2 1987 IV55 IV63
15. M.J. Holroyde, S.P. Robertson, J.D. Johnson, R.J. Solaro, and J.D. Potter The calcium and magnesium binding sites on cardiac troponin and their role in the regulation of myofibrillar adenosine triphosphatase J Biol Chem 255 1980 11688 11693
16. J.C. Lee, and S.E. Downing Cyclic AMP and the pathogenesis of myocardial injury Res Commun Chem Pathol Pharmacol 27 1980 305 318
17. P.A. Martorana The role of cyclic AMP in isoprenaline-induced cardiac necroses in the rat J Pharm Pharmacol 23 1971 200 203
18. T. Podzuweit, W.F. Lubbe, and L.H. Opie Cyclic adenosine monophosphate, ventricular fibrillation, and antiarrhythmic drugs Lancet 1 1976 341 342
19. P. Ebbesen Myocardial degeneration in mice treated with dibutyryl cyclic AMP and/or theophylline Virchows Arch, A Pathol Anat Histopathol 372 1976 89 95
20. M.J. Rell, E.M. Kline, and E.R. Bates Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure Am Heart J 112 1986 787 791
21. M. Packer, J.R. Carver, and R.J. Rodeheffer Effect of oral milrinone on mortality in severe chronic heart failure N Engl J Med 325 1991 1468 1475
22. T.H. LeJemtel Review of a dose-dependent increase in mortality with vesnarinone among patients with severe heart failure Curr Cardiol Rep 1 1999 31
23. J.N. Cohn, S.O. Goldstein, and B.H. Greenberg A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators N Engl J Med 339 1998 1810 1816
24. C.M. O'Connor, W.A. Gattis, and B.F. Uretsky Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST) Am Heart J 138 1999 78 86
25. S. Thackray, K. Witte, A.L. Clark, and J.G. Cleland Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT Eur J Heart Fail 2 2000 209 212
26. G.M. Felker, R.L. Benza, and A.B. Chandler Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study J Am Coll Cardiol 41 2003 997 1003
27. M.S. Caffe, R.M. Califf, and K.F Adams Jr. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial JAMA 287 2002 1541 1547
28. M. Gheorghiade, W.A. Gattis, and L. Klein OPTIME in CHF trial: rethinking the use of inotropes in the management of worsening chronic heart failure resulting in hospitalization Eur J Heart Fail 5 2003 9 12
29. J.M. Cruickshank The xamoterol experience in the treatment of heart failure Am J Cardiol 71 1993 61C 64C
30. The Xamoterol in Severe Heart Failure Study Group Xamoterol in severe heart failure Lancet 336 1990 1 6 [Erratum in]
31. Lancet 336 1990 (Sep 15) 698
32. M. Tango, K. Lyngborg, J. Mehlsen, T.L. Svendsen, and J. Trap-Jensen Xamoterol in severe congestive heart failure: long-term oral treatment, a double-blind randomised study Int J Cardiol 34 1992 63 68
33. B.F. Uretsky, M. Jessup, and M.A. Konstam Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group Circulation 82 1990 774 780
34. M. Fowler Beta-adrenergic blocking drugs in severe heart failure Rev Cardiovasc Med 3 Suppl. 3 2002 S20 S26
35. K.C. Wollert, and H. Drexler Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol as the sun and center of the beta-blocker world? Circulation 106 2002 2164 2166
36. M. Packer, M.B. Fowler, and E.B. Roecker Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study Circulation 106 2002 2194 2199
37. H. Krum, E.B. Roecker, and P. Mohacsi Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study JAMA 289 2003 712 718
38. S.F. Shakar, W.T. Abraham, and E.M. Gilbert Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure J Am Coll Cardiol 31 1998 1336 1340
39. F. Dies, M.J. Krell, and P. Whiytlow Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure Circulation 74 Suppl. 2 1986 II-38
40. F. Oliva, R. Latini, and A. Politi Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial Am Heart J 138 1999 247 253
41. J.B. Young, and E.K. Moen Outpatient parenteral inotropic therapy for advanced heart failure J Heart Lung Transplant 19 8 Suppl. 2000 S49 S57
42. L. Vecchia, R. Ometto, G. Finocchi, and M. Vincenzi Torsade de pointes ventricular tachycardia during low dose intermittent dobutamine treatment in a patient with dilated cardiomyopathy and congestive heart failure Pacing Clin Electrophysiol 22 1999 397 399
43. A.L. Marius-Nunez, L. Heaney, and R.N. Fernandez Intermittent inotropic therapy in an outpatient setting: a cost-effective therapeutic modality in patients with refractory heart failure Am Heart J 132 1996 805 808
44. L.W. Miller Outpatient dobutamine for refractory congestive heart failure: advantages, techniques, and results J Heart Lung Transplant 10 1991 482 487
45. M.M. Applefeld, K.A. Newman, and F.J. Sutton Outpatient dobutamine and dopamine infusions in the management of chronic heart failure: clinical experience in 21 patients Am Heart J 114 1987 589 595
46. J.B. Young, and E.K. Moen Outpatient parenteral inotropic therapy for advanced heart failure J Heart Lung Transplant 19 8 Suppl. 2000 S49 S57
47. S. Yusuf, and K.K. Teo Inotropic agents increase mortality in patients with congestive heart failure (abstract) Circulation 82 Suppl. III 1990 673
48. A.J. Burger, U. Elkayam, and M.T. Neibaur Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy Am J Cardiol 88 2001 35 39
49. A.J. Burger, D.P. Horton, and T. LeJemtel Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study Am Heart J 144 2002 1102 1108
50. G. Boudreau, F. Peronnet, J. De Champlain, and R. Nadeau Presynaptic effects of epinephrine on norepinephrine release from cardiac sympathetic nerves in dogs Am J Physiol 265 1993 H205 H211
51. D.V. Unverferth, M. Blanford, R.E. Kates, and C.V. Leir Tolerance to dobutamine after a 72 hour continuous infusion Am J Med 69 1980 262 266
52. O. Hansen, B.W. Johansson, and B. Gullberg Clinical outcome of acute myocardial infarction in patients on treatment with beta-blockers or calcium antagonists. A study of 7,922 hospitalized first myocardial infarctions Cardiology 80 1992 382 391
53. B.W. Johansson Effect of beta blockade on ventricular fibrillation- and ventricular tachycardia-induced circulatory arrest in acute myocardial infarction Am J Cardiol 57 1986 34F 37F
54. A.D. Struthers, and J.L. Reid Adrenaline causes hypokalaemia in man by beta 2 adrenoceptor stimulation Clin Endocrinol 20 1984 409 414
55. E. Braunwald, D. Zipes, and P. Libby Heart disease: a textbook of cardiovascular medicine 6th ed. 2001 WB Saunders Co. Philadephia, PA 455522 455524
56. Enoximone plus extended-release metoprolol succinate in subjects with advanced chronic heart failure. Available at: http://www.clinicaltrials.gov/ct/ show/NCT.htm. Accessed October 14, 2004.
57. E.F. Du Toit, C.A. Muller, J. McCarthy, and L.H. Opie Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart J Pharmacol Exp Ther 290 1999 505 514
58. H.C. Doval, D.R. Nul, H.O. Grancelli, S.V. Perrone, G.R. Bortman, and R. Curiel Randomised trial of low-dose amiodarone in severe congestive heart failure Lancet 344 1994 493 498
59. S.N. Singh, R.D. Fletcher, and S.G. Fisher Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia N Engl J Med 333 1995 77 82
60. A.J. Moss, W.J. Hall, and D.S. Cannom Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia N Engl J Med 335 1996 1933 1940
61. J. Levijoki, P. Pollesello, and J. Kaivola Further evidence for the cardiac troponin C mediated calcium sensitization by levosimedan: structure-response and binding analysis with analogs of levosimendan J Mol Cell Cardiol 32 2000 470 491
62. H. Haikala, and I.B. Linden Mechanisms of action of calcium-sensitizing drugs J Cardiovasc Pharmacol 26 Suppl. 1 1995 S10 S19
63. L. Mathew, and S.D. Katz Calcium sensitising agents in heart failure Drugs Aging 12 1998 191 204
64. C. Holubarsch New inotropic concepts: rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors Cardiology 88 Suppl. 2 1997 12 20
65. C. Holubarsch, J. Ludemann, and S. Wiessner Shortening versus isometric contractions in isolated human failing and non-failing left ventricular myocardium: dependency of external work and force on muscle length, heart rate and inotropic stimulation Cardiovasc Res 37 1998 46 57
66. J. Lubsen, H. Just, and A.C. Hjalmarsson Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial Heart 76 1996 223 231
67. F. Follath, J.G. Cleland, and H. Just Study efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial Lancet 360 2002 196 202
68. V.S. Moiseyev, P. Poder, and N. Andrejevs Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN) Eur Heart J 23 2002 1422 1432
69. H. Haikala, E. Nissinen, E. Etemadzadeh, J. Levijoki, and I.B. Linden Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation J Cardiovasc Pharmacol 25 1995 794 801
70. H. Haikala, P. Kaheinen, J. Levijoki, and I.B. Linden The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan Cardiovasc Res 34 1997 536 546
71. ClinicalTrials.gov Web site. Levosimendan versus dobutamine in shock patients. Available at: http://www.clinicaltrials.gov/ct/show/NCT00093301. Accessed November 9, 2004.
72. F. Franco, P. Monteiro, and J. Correia Levosimendan is safe and effective in patients with severe low cardiac output heart failure and critical hypotension J Am Coll Cardiol 43 (5) Suppl. A 2004 1088 1125 [Abstract]
73. A. Oldner, D. Konrad, E. Weitzberg, A. Rudehill, P. Rossi, and M. Wanecek Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock Crit Care Med 29 2001 2185 2193
74. 2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes Eur J Pharmacol 333 1997 249 259
75. M.S. Nieminen, J. Akkila, and G. Hasenfuss Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure J Am Coll Cardiol 36 2000 1903 1912
76. J. Lilleberg, M.S. Nieminen, and J. Akkila Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting Eur Heart J 19 1998 660 668